Using positron emission tomography (PET) and an acute dopamine depletion challenge it is possible to estimate endogenous dopamine levels occupying dopamine D 2/3 receptors (D 2/3 R) in humans in vivo. Our group has developed [ 11 C]-( þ )-PHNO, the first agonist radiotracer with preferential in vivo affinity for D 3 R. Thus, the use of [
INTRODUCTION
The dopamine system has been a key molecular target in understanding the etiology and treatment of numerous neuropsychiatric disorders. Not surprisingly, it has been the most heavily investigated neurotransmitter system in the living human brain using the molecular imaging technique, positron emission tomography (PET) (Banerjee and Prante, 2012) . Using radiolabelled dopamine D 2/3 receptor (D 2/3 R) antagonists, such as [
C]-raclopride, [
18 F]-fallypride, and [
11 C]-FLB 457, it has been possible to quantify the availability of D 2/3 R in vivo in the brains of healthy persons and persons with neuropsychiatric disease (Gjedde et al, 2005; Newberg et al, 2011; Tatsch and Poepperl, 2012) . Studies in vitro demonstrate that D 2/3 R exists in multiple affinity states for its endogenous ligand dopamine (Cumming, 2011; Seeman, 2013; van Wieringen et al, 2013) . These states seem to affect the binding of agonist, but not antagonist, radioligands in vitro (Cumming, 2011; Seeman, 2013; van Wieringen et al, 2013) . Therefore, the use of agonist radiotracers for D 2/3 R may reveal a more physiologically relevant quantification of D 2/3 R availability in the human brain, being sensitive to changes in receptor affinity. The PET radiotracer [ 11 C]-( þ )-PHNO is the first agonist radiotracer for D 2/3 R, which has preferential affinity for the D 3 receptors (Graff-Guerrero et al, 2010; Graff-Guerrero et al, 2008; Narendran et al, 2006; Rabiner et al, 2009; Wilson et al, 2005) . This unique property of [ 11 C]-( þ )-PHNO, B20-40-fold selectivity of D 3 R over D 2 R (Freedman et al, 1994; Gallezot et al, 2012; Rabiner et al, 2009; Searle et al, 2010; Seeman et al, 1993) , results in a differential contribution of D 2 R and D 3 R to the [ C]-( þ )-PHNO signal in vivo in humans attributed to D 3 R across ROIs are: the substantia nigra (SN) (B100%), hypothalamus (B100%), ventral pallidum (VP) (B75%), globus pallidus (GP) (B65%), ventral striatum (B26%), and dorsal caudate-putamen (negligible) (GraffGuerrero et al, 2010; Searle et al, 2013; Tziortzi et al, 2011) .
Like the antagonist radiotracer [ 11 C]-raclopride, endogenous dopamine competes with [
11 C]-( þ )-PHNO for binding to D 2/3 R at baseline Shotbolt et al, 2012; Willeit et al, 2008) . The amount of endogenous dopamine occupying D 2/3 R at baseline can be estimated with such radioligands by comparing the percent change in binding potential (BP ND ) between a baseline scan and a scan under acute dopamine depletion (Cumming et al, 2002; Laruelle et al, 1997; Verhoeff et al, 2001) . Acute dopamine depletion is achieved in humans using alphamethyl-para-tyrosine (AMPT), a competitive inhibitor of tyrosine hydroxylase, which is the rate-limiting enzyme of catecholamine synthesis. Using this paradigm, altered levels of striatal endogenous dopamine occupying D 2/3 R at baseline in neuropsychiatric disorders has been demonstrated (Abi-Dargham et al, 2000; Abi-Dargham et al, 2009; Bloemen et al, 2013; Kegeles et al, 2010; Martinez et al, 2009) .
To date, endogenous dopamine levels have not been estimated in humans using an agonist radiotracer for D 2/3 R, as opposed to an antagonist. The use of an agonist radiotracer, which should more closely mimic the binding of the endogenous ligand, may offer a more sensitive and functionally significant estimate of endogenous dopamine in humans. Moreover, endogenous dopamine levels have not been estimated in D 3 R-rich regions in humans such as the SN, GP, VP, and hypothalamus. The current investigation sought to validate the use of [
11 C]-( þ )-PHNO to estimate endogenous dopamine levels at D 2 R and D 3 R in healthy humans.
MATERIALS AND METHODS

Subjects
Healthy participants (24) were recruited for the study. Six participants failed screening. Two participants withdrew before the first baseline PET scan. One participant withdrew during the baseline PET scan owing to nausea induced by the [ 11 C]-( þ )-PHNO injection. One participant was unable to complete the study owing to [ 11 C]-( þ )-PHNO tracer problems before the post-AMPT PET scan. One participant withdrew before the post-AMPT PET scan owing to akathisia, and three participants withdrew during the post-AMPT scan owing to feelings of claustrophobia/ anxiety. Ten participants (4 female; mean age ¼ 29.1 ± 8.4) in total completed both PET scans, under the baseline and dopamine-depleted condition. All participants were free of any major medical or psychiatric disorder as determined by clinical interview, the Mini-International Neuropsychiatric Interview, basic laboratory tests, and electrocardiogram. Participants were required to have a negative urine screen for drugs of abuse and/or pregnancy at inclusion and before each PET scan. All participants were non-smokers. The study was approved by the Research Ethics Board of the Centre for Addiction and Mental Health (CAMH), Toronto, and no objection letter was issued by Health Canada. All the participants provided written and informed consent.
Metyrosine/AMPT Administration
Dopamine depletion was induced by oral administration of 64 mg of metyrosineper kilogram of body weight over 25 h. Independent of weight, no participant was dosed above 4500 mg. Metyrosine was administered in six equal doses at the following times: 0900, 1230 hours (post 3.5 h), 1700 hours (post 8 h), and 2100 hours (post 12 h) on day 1, and 0600 hours (post 21 h) and 1000 hours (post 25 h) on day 2. The post-AMPT PET scan was scheduled at 1200 hours, 28 h after the initial metyrosine dose. For two participants, the 1200-hour scan was unavailable, therefore the times for the doses were modified to reflect the 28-h post-AMPT PET scan. The subjects were under direct observation during AMPT administration and slept overnight on an inpatient unit at CAMH to ensure the AMPT dosing schedule and monitor for potential side effects. In addition, subjects were instructed to drink at least 4 l of fluids during the 2-day admission to prevent the formation of AMPT crystals in urine. Fluid intake was carefully monitored during the study to ensure compliance. Urine samples were collected at 1400 hours on day 1 and at 0900 hours on day 2 to monitor AMPT crystals in urine. In addition, in order to alkalinize the urine, which increases AMPT solubility, sodium bicarbonate (1.25 g) was given orally at 2200 hours on the evening before day 1 and at 0700 hours on day 1 of administration.
Plasma Samples
Plasma levels of prolactin, homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) were collected at 0900 hours (day 1, before AMPT administration), 1400 hours (day 1) and 1200 hours (day 2). Plasma levels of AMPT were also collected at 1400 hours (day 1) and 1200 hours (day 2). Plasma prolactin, HVA, MHPG, and AMPT were quantified as previously described (Verhoeff et al, 2002) . The times were modified for the two participants with the alternative post-PET scan times.
Rating Scales
Subjects were evaluated by the research psychiatrists (SN, GR, PG, and AG-G) for potential side effects at the following times: 0900 hours (baseline), 1400 hours (post 5 h dose), 1200 hours (post 27 h dose), and at 1500 hours (post 30 h dose) The times were modified for the two participants with the alternative post-PET scan times. The presence of adverse effects such as parkinsonian symptoms, acute dystonias, and involuntary movements was monitored using the Simpson Angus Scale (SAS), Barnes Akathisia Scale (BAS), and the Abnormal Involuntary Movement Rating Scale (AIMS). To evaluate changes in energy, mood, and subjective well-being induced by dopamine depletion, the Profile of Mood States (POMS) and the Subjective WellBeing Under Neuroleptic Treatment (SWN) scales were administered.
PET Imaging
Participants underwent two [
11 C]-( þ )-PHNO PET scans, one under baseline conditions and another at 25 h of starting AMPT-induced dopamine depletion. The radiosynthesis of [
11 C]-( þ )-PHNO and the acquisition of PET images has been described in detail elsewhere (GraffGuerrero et al, 2010; Wilson et al, 2000; Wilson et al, 2005) . Briefly, images were acquired using a high-resolution head-dedicated PET camera system (CPS-HRRT; Siemens Molecular Imaging, USA), which measures radioactivity in 207 brain slices with a thickness of 1.2 mm each. The inplane resolution was B2.8 mm full-width at half-maximum. Transmission scans were acquired using a 137 Cs (T 1/2 ¼ 30.2 years, E ¼ 662 KeV) single-photon point source to provide Baseline dopamine levels at D 2 and D 3 receptors F Caravaggio et al attenuation correction, and the emission data were acquired in list mode. The raw data were reconstructed by filteredback projection. For the baseline [ 11 C]-( þ )-PHNO scans, the mean radioactivity dose was 9.2(±1.2) mCi, with a specific activity of 1113.7( ± 328.2) mCi/mmol, and an injected mass of 2.1( ± 0.4) mg. For the dopamine-depleted scans, the mean radioactivity dose was 8.7(±1.5) mCi, with a specific activity of 1024.1( ± 299.5) mCi/mmol, and an injected mass of 2.1( ± 0.3) mg. There was no difference in mean radioactivity dose (t (9) 
Image Analysis
The ROI-based analysis for [ 11 C]-( þ )-PHNO has been described in detail elsewhere (Graff-Guerrero et al, 2008; Tziortzi et al, 2011) . Briefly, time activity curves (TACs) from ROIs were obtained from the dynamic PET images in native space with reference to each subjects co-registered MRI image. The co-registration of each subject's MRI to PET space was done using the normalized mutual information algorithm (Studholme et al, 1997) as implemented in SPM2 (SPM2, Wellcome Department of Cognitive Neurology, London; http://www.fil.ion.ucl.ac.uk/spm). The TACs were analyzed using the Simplified Reference Tissue Method (SRTM) (Lammertsma and Hume, 1996) , using the cerebellum as the reference region, to derive a quantitative estimate of binding: the binding potential relative to the non-displaceable compartment (BP ND ) as defined by the consensus nomenclature for in vivo imaging of reversibly binding radioligands (Innis et al, 2007) . The basis function implementation of the SRTM (Gunn et al, 1997) was applied to the dynamic PET images to generate parametric voxelwise BP ND maps using PMOD (v2.7, PMOD Technologies, Zurich, Switzerland). These images were spatially normalized into MNI brain space by nearest neighbor interpolation with a voxel size fixed in 2 Â 2 Â 2 mm 3 using SPM2. Regional BP ND estimates were then derived from ROIs defined in MNI space. The ventral striatum and dorsal striatum (dorsal caudate, hereafter caudate, and dorsal putamen, hereafter putamen) were defined according with Mawlawi et al (2001) . The GP, VP, and hypothalamus ROIs were defined according to the criteria of Tziortzi et al (2011) .
Estimating Endogenous Dopamine Levels
Our estimate of endogenous dopamine levels at D 2/3 R is based on the occupancy model, in which endogenous dopamine competes with the binding of radiotracers such as [
11 C]-( þ )-PHNO for D 2/3 R at baseline (Laruelle, 2000; Laruelle et al, 1997; Verhoeff et al, 2001) . It is assumed by this model that, (i) baseline D 2/3 R BP ND is confounded by endogenous dopamine, such that the higher the concentration of dopamine the lower the value of D 2/3 R BP ND will be obtained, (ii) D 2/3 R BP ND under depletion more accurately reflects the true status of D 2/3 R, and (iii) the fractional increase in D 2/3 R BP ND after dopamine depletion (ie, 100 Â (depletion BP ND À baseline BP ND )/baseline BP ND ¼ % DBP ND ) is linearly proportional to the baseline dopamine concentration at D 2/3 R, provided the process of dopamine depletion does not change the number and affinity of the D 2/3 R. Thus, the %DBP ND , under appropriate assumptions, is considered a semiquantitative index of endogenous dopamine levels at D 2/3 R (Verhoeff et al, 2001 ).
Statistical Analysis
Statistical analyses were conducted using SPSS (v.12.0; SPSS, Chicago, Illinois) and GraphPad (v.5.0; GraphPad Software, La Jolla, California). Normality of variables was determined using the D'Agostino-Pearson test. The significance level for all tests was set at po0.05 (two-tailed).
RESULTS
AMPT-Induced DBP ND
AMPT-dopamine depletion significantly increased [ Figure 1b ).
Plasma Results
The average plasma concentration of AMPT after 27 h of oral administration was 24( ± 11)mg/ml. On the basis of this average plasma concentration of AMPT, the average tyrosine hydroxylase inhibition in our sample can be estimated to be B80% (Engelman et al, 1968; Laruelle et al, 1997; Udenfriend et al, 1965) . AMPT-dopamine depletion significantly decreased plasma levels of HVA (t(9) ¼ 3.32, p ¼ 0.009) and MHPG (t(9) ¼ 5.72, p ¼ 0.0003) compared with baseline (see Table 1 ). AMPT-dopamine depletion significantly increased plasma levels of prolactin (t(9) ¼ 5.83, p ¼ 0.0003). Baseline levels of HVA and MHPG did not correlate with baseline [ 
SUV before and after AMPT
The averaged standard uptake values (SUVs) of [ 
Self-Reported Measures
POMS. AMPT-dopamine depletion significantly increased self-reported fatigue (t(9) ¼ 3.50, p ¼ 0.0068), decreased vigor (t(9) ¼ 3.75, p ¼ 0.0046), and increased tension (t(9) ¼ 2.31, p ¼ 0.046). However, changes in self-reported tension did not survive false discovery rate (FDR) correction (see Table 2 ). We investigated whether changes in selfreported fatigue and vigor were related to changes in [ SWN. AMPT-dopamine depletion significantly decreased self-reported physical functioning (t(9) ¼ 3.28, p ¼ 0.009), negative sum scores (t(9) ¼ 3.22, p ¼ 0.01), and emotion regulation (t(9) ¼ 2.26, p ¼ 0.049). However, only changes in negative sum scores survived FDR correction (see Table 2 ). Change in negative sum scores were not correlated with change in [
11 C]-( þ )-PHNO BP ND in any ROI. Baseline dopamine levels at D 2 and D 3 receptors F Caravaggio et al
Presence of Adverse Events
There was a trend for significant change in total scores on the SAS (t(9) ¼ 2.25, p ¼ 0.05), but no change in the sum of global clinical scores on the BAS (t(9) ¼ 1.00, p ¼ 0.34), as assessed from baseline to 30 h post AMPT-dopamine depletion. There was also no change in a total score of zero on the AIMS. However, like previous dopamine-depletion studies, it was clinically observed that subjects experienced strong AMPT side effects. This is indicated by our four participant withdrawals before the post-AMPT PET scan (one owing to severe akathisia and three owing to feelings of claustrophobia/anxiety). Notably, subject #4 and #5 presented with clinically notable akathisia and all subjects reported fatigue (for a list of all subjects and their BP ND data, see Supplementary Table 2 ). Perhaps these observations were not captured by our scales due to the timing of when these scales were administered throughout the study. Urine testing revealed that subject #8 developed a significant level of crystalluria given AMPT-dopamine depletion, and was treated after the post-PET scan accordingly.
DISCUSSION
The present investigation is the first to estimate endogenous dopamine levels at D 2/3 R using an agonist radiotracer:
Hypothetically, an agonist radiotracer for D 2/3 R should be more sensitive to changes in endogenous dopamine levels than an antagonist radiotracer. Notably, the change in striatal BP ND of [ 11 C]-( þ )-PHNO after dopamine depletion reported here (B30%) is much greater than has been previously reported in healthy controls using the antagonist radiotracer [ 11 C]-raclopride (B5.7-18.3%) (Kegeles et al, 2010; Martinez et al, 2009; Verhoeff et al, 2003; Verhoeff et al, 2002; Verhoeff et al, 2001) . This may be due to [ (Shotbolt et al, 2012; Willeit et al, 2008) . However, it is worth noting that although this increased sensitivity to endogenous dopamine has been demonstrated in vivo in humans, rodents (Kiss et al, 2011) , and cats , this finding is not ubiquitous across studies McCormick et al, 2011) . Furthermore, there are Baseline dopamine levels at D 2 and D 3 receptors F Caravaggio et al differences in the amount of AMPT administered across studies. However, in our sample we achieved a similar average plasma concentration of AMPT, and likely tyrosine hydroxylase inhibition, as previous studies (Kegeles et al, 2010; Martinez et al, 2009; Verhoeff et al, 2003; Verhoeff et al, 2002; Verhoeff et al, 2001 ). Finally, we cannot rule out that differences in reported dopamine estimation may be explained by differences in PET camera resolution. Directly comparing the change in [ The magnitude of %DBP ND varied across ROIs. Differences in the concentrations of dopamine in these regions may explain some of the observed difference in the %DBP ND. Investigations in rodent brains and post-mortem human brains generally support that the regional concentrations of dopamine are: VS4putamen4or ¼ caudate4GP4 hypothalamus4SN (Adolfsson et al, 1979; Versteeg et al, 1976 ). In our current investigation, the magnitude of %DBP ND generally followed this difference in regional dopamine concentration: VS4putamen ¼ caudate4GP4SN. It has been suggested that the dopamine concentration in the human GP is one-third of that in the striatum (Adolfsson et al, 1979) . Notably, the magnitude of %DBP ND between the GP and striatal ROIs differed by one-third. Finally, our observation of a B33-36% DBP ND in the striatum ROIs is in accordance with the 34% change in specific binding seen with [ 11 C]-( þ )-PHNO in rodent striata after dopamine depletion with AMPT and reserpine ex vivo (Wilson et al, 2005) . However, differences in regional concentrations in dopamine cannot explain the large %DBP ND observed in the hypothalamus. We do not think this observation can be easily explained by the greater affinity of [ 11 C]-( þ )-PHNO for D 3 R over D 2 R, as the %DBP ND varied across all the D 3 Rrich regions. Likewise, any potential non-tracer conditions at D 3 R cannot readily explain the large magnitude of %DBP ND observed in the hypothalamus and VP, especially as such conditions should reduce changes in BP ND due to dopamine (Laruelle, 2000) . Future studies are required to replicate these observations with larger sample sizes.
Despite following the ROI segmentation guidelines of Tziortzi et al (2011) , we were unable to reliably estimate [ group has noted the reliability of fitting in these regions is less than for the other ROIs. Thus, this may have contributed to the low statistical significance of the AMPT effect despite a high average change in BP ND . However, it is reassuring that our reported BP ND values for these regions are in accordance with the reports of other studies (Tziortzi et al, 2011) . Moreover, we may have been underpowered to detect significant changes in these regions, given their reliability of fitting. Notably, no study has ever published test-retest reliability data for the hypothalamus and VP ROIs with [ 11 C]-( þ )-PHNO. Although this poses a limitation to our current investigation, it does not detract from the fact that after AMPT, large average increases in BP ND were observed in these ROIs. Future studies would benefit from reporting test-retest reliability of fitting for these ROIs.
Consistent with previous reports (Verhoeff et al, 2003) , AMPT significantly decreased self-reported vigor and increased self-reported fatigue in healthy participants. Interestingly, the change in vigor scores under dopamine depletion was related to the change in [
11 C]-( þ )-PHNO BP ND in the GP. Several case studies have reported that unilateral or bilateral lesions to the GP, in particular the internal segment, can result in profound apathy and lack of motivation (Adam et al, 2013; Singh et al, 2011; Vijayaraghavan et al, 2008) . It has also been demonstrated that D 3 R are more abundant in the internal segment of the GP than D 2 R (Gurevich and Joyce, 1999) . Thus, we speculate that the significant decrease in vigor and motivation seen in participants after dopamine depletion may be mediated by reduced dopaminergic signaling at D 3 R in the GP, as captured by the change in [
There are several limitations with the current investigation worth addressing. First, our study was only single-blind and not placebo controlled, a limitation shared by all previous dopamine PET studies using AMPT. Second, we have not collected arterial plasma data, quantifying BP ND using the SRTM rather than using full-kinetic modeling. The SRTM approach to estimate BP ND with the cerebellum as reference has a good correlation with the BP as estimated with a full-kinetic analysis and it was validated in controls for [ (Ginovart et al, 2007) . The full-kinetic analysis would allow direct estimation of the BP in the ROIs without the potential bias induced by specific binding in the reference region, if any. Simply, we cannot rule out (quantitatively) that AMPT did not exert an effect in the reference tissue, and poses as a current limitation to our study. Finally, it has been noted that the injected mass of [ 11 C]-( þ )-PHNO was not within ideal radiotracer conditions (ie, o1.5 ng/kg) and consequently could lead to an underestimation of the occupancy by endogenous dopamine (see appendix in (Shotbolt et al, 2012) ). Unfortunately the specific activity required to obtain tracer conditions is not possible with the available radiosynthesis method. We do not believe this unavoidable technical limitation substantially changes the conclusion of our study. As the radiotracer mass injected was similar in both PET scan sessions, we are underestimating the apparent occupancy of the competitor dopamine by a similar factor in both scans. Furthermore, the PET scans were performed 424 h apart avoiding any carry-over effect.
In conclusion, the current investigation is the first to estimate endogenous dopamine levels at D 2 R and D 3 R in healthy humans using the agonist radiotracer [
11 C]-( þ )-PHNO is sensitive to acute dopamine depletion in humans, and future studies employing this radiotracer to estimate endogenous dopamine levels at D 2 R and D 3 R in neuropsychiatric populations are warranted.
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